Sanyou Bio: Sanyou's Intelligence-Enabled Innovative Biologics R&D Platform Leads in the New Era of Biological Drug Development

SHANGHAI, March 27, 2024 /PRNewswire/ -- Dr. Guojun Lang, founder and CEO of Sanyou Biopharmaceuticals provides industry insights: The new era sees the transition towards digitalization and intelligence. Following this trend, we have been thinking and planning the transformative path of digitalization and intelligence as well. What was once impossible has gradually become reality—future R&D services will be built...

Related Keywords

London ,City Of ,United Kingdom ,Boston ,Massachusetts ,United States ,Shanghai ,China ,Philadelphia ,Pennsylvania ,San Diego ,California ,Sanyou Bio ,Guojun Lang ,Primer Design Program ,Drug Development ,Drug Development System ,Sequence Analysis Program ,Sanyou Biopharmaceuticals Co Ltd ,Sanyou Biopharmaceuticals ,Advantage Brought ,Business Models ,Major Systems ,Project Management System ,Management System ,Academic Customer Map ,Analysis Program ,Design Program ,Data Processing System ,Development System ,Drug Developability Modeling System ,Biological Drug ,Parallel Computing ,